about
Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugsLiposomal delivery systems for intestinal lymphatic drug transportThe interaction of lipophilic drugs with intestinal fatty acid-binding protein.Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies.Revisiting the rule of five on the basis of pharmacokinetic data from rat.Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery.Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation.Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.Advanced drug delivery to the lymphatic system: lipid-based nanoformulations.Current methods for predicting human food effect.Modeling kinetics of subcellular disposition of chemicals.Convective diffusion of nanoparticles from the epithelial barrier toward regional lymph nodesEngineering strategies to enhance nanoparticle-mediated oral delivery.Mechanisms of microemulsion enhancing the oral bioavailability of puerarin: comparison between oil-in-water and water-in-oil microemulsions using the single-pass intestinal perfusion method and a chylomicron flow blocking approach.Nanostructured lipid carriers: versatile oral delivery vehicle.Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake.Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs.Lipid-based oral multiparticulate formulations - advantages, technological advances and industrial applications.Self-microemulsifying drug delivery system (SMEDDS)--challenges and road ahead.Recent approaches of lipid-based delivery system for lymphatic targeting via oral route.Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects.Immunosuppressive drug therapy--biopharmaceutical challenges and remedies.Self-assembled structures formed during lipid digestion: characterization and implications for oral lipid-based drug delivery systems.Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs.Biological voyage of solid lipid nanoparticles: a proficient carrier in nanomedicine.Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.A trial for the design and optimization of pH-sensitive microparticles for intestinal delivery of cinnarizine.Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.Excipient Nanoemulsions for Improving Oral Bioavailability of Bioactives.Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.Long-chain triglycerides-based self-nanoemulsifying oily formulations (SNEOFs) of darunavir with improved lymphatic targeting potential.Preparation, Characterization and Evaluation of Quetiapine Fumarate Solid Lipid Nanoparticles to Improve the Oral Bioavailability.Systematic development of optimized SNEDDS of artemether with improved biopharmaceutical and antimalarial potential.The In Vitro Lipolysis of Lipid-Based Drug Delivery Systems: A Newly Identified Relationship between Drug Release and Liquid Crystalline Phase.Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action.Freeze-dried targeted mannosylated selenium-loaded nanoliposomes: development and evaluation.In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of ClarithromycinEnhanced oral bioavailability of griseofulvin via niosomes.Enhanced oral absorption of halofantrine enantiomers after encapsulation in a proliposomal formulation.
P2860
Q26774831-DBD5390C-2DC3-4586-92DE-01E425CC63BEQ28067324-99E772F5-61A7-45D0-BED7-4BA50B2EBC60Q30983194-B1D722CF-FD47-4AF9-AF2C-11B5B4351BD4Q33568609-6C491498-A953-4F99-B85C-A6085BB11CFBQ34024247-BCFAD659-F31E-4D5E-97C7-69F059ECA9C8Q34733880-4588A9CB-5869-4DC2-A462-600C69004196Q35957617-CF699419-9FE4-419C-B90E-73EBD46DDFB1Q36748145-2C224538-6400-49CF-AEBD-6FCF4F0317E4Q37003034-9533DF8F-91B9-4582-AC86-A3871FACBD4AQ37066550-FEF5C75D-7F3B-4873-8EDD-B678FBEBDF02Q37171894-CB3E0587-5C75-4AED-8CC7-E82BEAB3DA84Q37194304-F24A9D32-8C6B-4F1B-A68F-B2BE8884DB8BQ37244096-A5ED1FE4-2D73-4987-8F32-3882D0136A43Q37328673-2D9DACCC-B220-4761-B53C-D404EC885581Q37336117-B4D21B51-3951-4EF9-A0F7-2BAD7560472DQ37474497-B1B3EA9E-AEFC-4D61-890E-69DCCDD19655Q37490613-DAEEADD2-B43C-4DAC-B9C2-F723A67ABD3EQ37702234-5D4D9261-7A94-4D5F-9EF3-46D4018AD331Q37826428-76CAF117-3800-445F-9253-C67752C2642DQ38199539-335FC6CA-B3DD-436F-BC8E-2F38575C229FQ38242314-B0AB96C1-57E7-41CB-B042-8EEA54E27F26Q38306645-8A19C7E3-51C7-42E4-829C-BC9C46446636Q38340831-0C0A8BA2-5344-4279-8E43-1AECFA0CB7FBQ38383061-6EF42E4B-199E-4557-A6BF-C20D4E7104AFQ38406190-8C95322E-8363-4D31-9164-5513308D21AEQ38558905-8C9EC83A-38EB-47F1-BE8D-0CCD1646999AQ38862706-C3FB0B20-0000-4535-9EBE-29BA934BFB9BQ38922778-2E2FBF38-828F-4866-92E0-0A810CFA3BD6Q38926514-3890D327-15D1-4C2D-B2F3-5C524C825B65Q39201371-81D97E5F-44DB-4FB6-8644-1587EA8A858AQ39913211-5F5268DB-407D-479E-B557-3C63A125172CQ40084144-E57E6941-B945-4CEE-9136-302F4CF6AFC0Q40335962-0E7EC872-CCE9-4492-A08D-3E91AADD38EFQ40737520-D5C7EC51-1990-4C8F-92F3-DBEC342CDF0CQ42178278-E7A5CAB0-0F8F-4984-8A3A-8BAC1E79A538Q42508659-B31ACF0E-29E3-4AD2-9366-BC3E7AC96752Q42574200-B64417F6-D07C-4CF0-AD19-F5E222FF14AFQ42753033-26183A2D-3D23-48D2-8113-E7FB4055A766Q42945601-1871EC0B-5725-4CF9-90D4-81286730921BQ44114259-12F19C88-D4E7-496D-8149-B8B74DD4800E
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Intestinal lymphatic drug transport: an update.
@ast
Intestinal lymphatic drug transport: an update.
@en
Intestinal lymphatic drug transport: an update.
@nl
type
label
Intestinal lymphatic drug transport: an update.
@ast
Intestinal lymphatic drug transport: an update.
@en
Intestinal lymphatic drug transport: an update.
@nl
prefLabel
Intestinal lymphatic drug transport: an update.
@ast
Intestinal lymphatic drug transport: an update.
@en
Intestinal lymphatic drug transport: an update.
@nl
P1476
Intestinal lymphatic drug transport: an update.
@en
P2093
P356
10.1016/S0169-409X(01)00151-X
P407
P577
2001-08-01T00:00:00Z